The KCTD9 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal A-549 cell population with disrupted KCTD9. This loss-of-function model, created through targeted gene disruption, preserves genomic heterogeneity and avoids clonal artifacts, making it ideal for rigorous functional studies.
A-549 is a human epithelial cell line derived from a lung adenocarcinoma of a 58-year-old Caucasian male, widely used as a model of alveolar type II epithelium and for studying lung adenocarcinoma biology. Its well-characterized signaling networks provide a relevant platform for investigating genes involved in tumorigenesis and therapy response.
KCTD9 functions as a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, facilitating the ubiquitination and proteasomal degradation of target proteins such as STING (TMEM173) and I??B??. Through this activity, KCTD9 negatively regulates STING-dependent innate immune responses and modulates NF-??B signaling by controlling I??B?? stability. The KCTD9-CUL3-RBX1-26S proteasome axis is activated by upstream cues including TNF?? stimulation and directly influences downstream effectors such as NF-??B (p65/p50) transcription factors, cell cycle regulators, and apoptotic cascades. KCTD9 interacts with core ligase components CUL3 and RBX1, as well as STING and other BTB-domain substrate recognition proteins.
Disruption of KCTD9 in A-549 lung adenocarcinoma cells is predicted to elevate STING protein levels, thereby potentiating innate immune signaling and interferon production, while simultaneously stabilizing I??B?? and altering NF-??B transcriptional dynamics. Such perturbations can impact cell proliferation, apoptosis, and sensitivity to chemotherapeutics, providing an experimentally tractable model to investigate tumor cell-intrinsic immune regulation and drug resistance. As KCTD9 has been implicated in hepatocellular carcinoma and glioblastoma, insights gained from this system may have broader translational relevance.
Applications span cancer biology, ubiquitin-proteasome studies, NF-??B signaling, innate immunity, and drug resistance research. Assays include western blotting, RT-qPCR, co-immunoprecipitation, ubiquitination assays, immunofluorescence, flow cytometry, NF-??B reporter and STING pathway activation assays, as well as cell proliferation, migration, and drug sensitivity testing. For additional information, please contact Ascent Research.
